Purchase this article with an account.
A. C. Cigna, M. V. Netto, J. Barreto, Jr., S. J. Bechara, W. Agmont, M. Cunha; Prophylactic Intraoperative Use of Mitomycin C Following Photorefractive Keratectomy (PRK) in Patients Previously Submitted to Penetrating Keratoplasty (PKP) and Significant Anisometropia. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5364.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze the results of prophylactic intraoperative use of mitomycin C (MMC) following photorefractive keratectomy (PRK) in patients previously submitted to penetrating keratoplasty (PKP) and significant anisometropia with no tolerance to contact lenses.
retrospective analysis of 23 eyes previously submitted to PKP that received MMC 0.02% intraoperatively (for 30 seconds).
Mean follow-up was 12 months (range, 9-18). Preoperative spherical equivalent refraction was - 5.24 +/- 3.32 diopters (D) and -1.15 +/- 0.92 postoperatively. Best spectacle-corrected visual acuity was 0.68 +/- 0.12 preoperatively and 0.72 +/- 0.14 postoperatively. Uncorrected visual acuity (UCVA) > or = 20/40 was obtained in 72.3% of cases; UCVA > or = 20/25 was achieved in 36.4% of cases. No corneal haze, side effects or toxic effects were documented during slit-lamp examination. No statistically significant decrease in endothelial cell count was evidenced at 3, 6 and 9 months postoperatively (p < 0.001).
Prophylactic use of intraoperative MMC following PRK in patients previously submitted to corneal transplant is apparently a safe and effective LASIK alternative for patients with significant anisometropia and contact lenses intolerance.
This PDF is available to Subscribers Only